Resumen
El alteplase es el único fibrinolítico actualmente autorizado en Colombia para el tratamiento del ACV isquémico agudo. El tenecteplase constituye una nueva alternativa de tratamiento en esta enfermedad al ofrecer mejor perfil farmacológico, mayor eficacia con mejores desenlaces mayores, porcentajes de recanalización, y con seguridad similar a la del alteplase. La posibilidad de desabastecimiento temporal de alteplase con disponibilidad de tenecteplase en Colombia abre la posibilidad de su uso en ACV isquémico agudo.
Citas
Tanswell P, Modi N, Combs D, Danays T. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet. 2002;41:1229-45.
Behrouz R. Intravenous tenecteplase in acute ischemic stroke: an updated review. J Neurol. 2014;261:1069-72.
Huang X, Moreton FC, Kalladka D, Cheripelli BK, MacIsaac R, Tait C. Coagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke. Stroke. 2015;46:3543-46
Haley EC, Lyden PD, Johnston KC, Hemmen TM, the TNK Stroke Investigators*. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke. 2005;36:607-12.
Haley EC, Thompson JLP, Grotta JC, Lyden PD, Hemmen TG, Brown DL. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke. 2010;41;707-11.
Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012; 366: 1099-107.
Huang X, Cheripelli BK, Lloyd SM, Kalladka D, Moreton FC, Siddiqui A et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol. 2015;14:368-76.
Logallo N, Novotny V, Assmus J, Kvistad CE, Alteheld L, Ronnnig OM et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol. 2017;16:781-88.
Ronnnig OM, Logallo N, Thommessen B, Tobro H, Novotny V, Kvistad CE et al. Tenecteplase versus alteplase between 3 and 4.5 hours in low National Institutes of Health Stroke Scale. Stroke. 2019;50:498-00.
Kvistad CE, Novotny V, Kurz MW, Ronnnig OM, Thommessen B, Carlsson M et al. Safety and outcomes of tenecteplase in moderate and severe ischemic stroke results from NOR-TEST. Stroke. 2019;50:1279-81.
Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med. 2018;378:1573-82.
Campbell BCV, Mitchel PJ, Churilov L, Yassi N, Kleinig TJ, Yan B et al. Determining the optimal dose of tenecteplase before endovascular therapy for ischemic stroke (EXTENDIA TNK Part 2) : A multicenter, randomized, controlled study. Int J Stroke 2019; 1747493019879652.
Campbell BCV, Majoie BLM, Albers GW, Menon BK, Yassi N, Sharma G et al. Penumbral imaging and functional outcome in patients with anterior circulation ischaemic stroke treated with endovascular thrombectomy versus medical therapy: a meta-analysis of individual patient-level data. Lancet Neurol. 2019;18:46-55.
Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ. Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke. The EXTEND-IA TNK Part 2 randomized clinical trial. JAMA. 2020;323:1257-65.
Huang X, MacIsaac R, Thompson JLP, Levin B, Buchsbaum R, Haley EC et al. Tenecteplase versus alteplase in stroke thrombolysis: An individual patient data meta-analysis of randomized controlled trials. Int J of Stroke. 2016;11(5):534-43.
Thelengana A, Radhakrishnan DM, Prasad M, Kumar A, Prasad K. Tenecteplase versus alteplase in acute ischemic stroke: systematic review and meta-analysis. Acta Neurol Belg. 2019;119:359-67.
Kheiri B, Osman M, Abdala A, Haykal T, Ahmed S, Hassan M et al. Tenecteplase versus alteplase for management of acute Ischemic stroke: a pairwise and network meta-analysis of randomized clinical trials. J Thromb Thrombolys. 2018;46:440-50.
Owais M, Panwar A, Valupadas C, Veeramalla M. Acute ischemic stroke thrombolysis with tenecteplase: an institutional experience from South India. Ann Afr Med. 2018;17(2):90-93.
Nepal G, Kharel G, Ahamad ST, Basnet B. Tenecteplase versus alteplase for the management of acute ischemic stroke in a low-income country-Nepal: Cost, efficacy, and safety. Cureus. DOI: 10.7759/cureus.2178
Powers WF, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 Update to the 2018 guidelines for the early management of acute ischemic stroke a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50: e344-e418. DOI: 10.1161/STR.0000000000000211.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.